Stany Zjednoczone - angielski - NLM (National Library of Medicine)

strides pharma inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)] . potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)] . potassium citrate extended-release tablets are contraindicated: • in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). • in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

akorn - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 50 mg in 2 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium cation 328 mg in 100 ml - sodium acetate injection, usp (4 meq per ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (4 meq per ml) is contraindicated in patients with hypernatremia or fluid retention.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hospira, inc. - sodium acetate anhydrous (unii: nvg71zz7p0) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37) - sodium acetate anhydrous 164 mg in 1 ml - sodium acetate injection, usp (2 meq/ml) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. sodium acetate injection, usp (2 meq/ml) is contraindicated in patients with hypernatremia or fluid retention.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hospira, inc. - sodium lactate (unii: tu7hw0w0qt) (lactic acid, unspecified form - unii:33x04xa5at, sodium cation - unii:lyr4m0nh37) - sodium lactate 5.6 g in 10 ml - sodium lactate injection, usp 50 meq (5 meq/ml), is primarily indicated, after dilution , as a source of bicarbonate for prevention or control of mild to moderate metabolic acidosis in patients with restricted oral intake whose oxidative processes are not seriously impaired. it is not intended nor effective for correcting severe acidotic states which require immediate restoration of plasma bicarbonate levels. sodium lactate has no advantage over sodium bicarbonate and may be detrimental in the management of lactic acidosis. sodium lactate injection, usp 50 meq is contraindicated in patients suffering from hypernatremia or fluid retention. it should not be used in conditions in which lactate levels are increased (e.g., shock, congestive heart failure, respiratory alkalosis) or in which utilization of lactate is diminished (e.g., anoxia, beriberi). not for use in the treatment of lactic acidosis.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose and sodium chloride injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose and sodium chloride injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary sodium and potassium are present in human breast milk. there are no data on the effects

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - sodium chloride injection, usp is indicated for parenteral restoration of sodium ion in patients with restricted oral intake.  sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome.  sodium chloride injection may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes. sodium chloride injection is contraindicated in patients with hypernatremia or fluid retention.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

fresenius kabi usa, llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - sodium chloride injection, usp, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion.  it is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs.  after available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from sodium chloride injection, usp, 23.4% and diluted for use. sodium chloride injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases.  isotonic sodium chloride injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. the toxic symptoms that follow various